Atrium Therapeutics, Inc. (RNA) shareholders
Close on Nov 17, 2026Market cap $110.85MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| John Petry Joint filing with Sessa Capital IM, L.P. (8.80%) | 1,500,000 | 8.80% | 13G (passive) | Jun 30, 2026 |
| T. Rowe Price Associates, Inc. | 1,472,984 | 8.60% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 1,135,757 | 6.60% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P. | 1,500,000 | 8.77% | $20.18M | +948,609 | 0.34% |
| Price T Rowe Associates Inc /Md/ | 1,472,984 | 8.61% | $19.81M | −80,226 | 0.00% |
| BlackRock, Inc. | 1,447,476 | 8.46% | $19.47M | +242,185 | 0.00% |
| Crcm LP | 1,283,078 | 7.50% | $17.26M | New | 5.68% |
| Vanguard Capital Management LLC | 730,831 | 4.27% | $9.83M | +103,962 | 0.00% |
| TIG Advisors, LLC | 561,533 | 3.28% | $7.55M | −46,019 | 0.33% |
| Arbiter Partners Capital Management LLC | 522,576 | 3.05% | $7.03M | +292,576 | 1.85% |
| Cantor Fitzgerald, L. P. | 513,834 | 3.00% | $6.91M | +278,197 | 0.04% |
| Geode Capital Management, LLC | 386,929 | 2.26% | $5.21M | +67,098 | 0.00% |
| Two Sigma Investments, LP | 345,481 | 2.02% | $4.65M | +166,921 | 0.00% |
| Goldman Sachs Group Inc | 310,341 | 1.81% | $4.17M | −39,609 | 0.00% |
| 683 Capital Management, LLC | 300,000 | 1.75% | $4.04M | – | 0.20% |
| State Street Corp | 271,762 | 1.59% | $3.66M | +14,676 | 0.00% |
| Slotnik Capital, LLC | 237,637 | 1.39% | $3.20M | +56,692 | 0.83% |
| Weiss Asset Management LP | 219,730 | 1.28% | $2.96M | −20,971 | 0.03% |
| Millennium Management LLC | 200,559 | 1.17% | $2.70M | +9,700 | 0.00% |
| Schonfeld Strategic Advisors LLC | 199,158 | 1.16% | $2.68M | +36,399 | 0.01% |
| Aqr Capital Management LLC | 172,235 | 1.01% | $2.32M | New | 0.00% |
| Nexpoint Asset Management, L.P. | 150,025 | 0.88% | $2.02M | – | 0.13% |
| Polar Asset Management Partners Inc. | 150,000 | 0.88% | $2.02M | +80,000 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 155 | 15M | 90.6% | 40 / 47 | 35 / 46 | 5M | 4M |
| Q1 2026 | 163 | 15M | 86.7% | 163 / 0 | 0 / 0 | 15M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
156 funds held RNA in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 566,428 | 3.31% | $7.62M | 0.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 518,416 | 3.03% | $6.97M | 0.00% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 443,263 | 2.59% | $5.96M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 377,354 | 2.21% | $5.08M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 188,626 | 1.10% | $2.54M | 0.00% | Jun 30, 2026 |
| BlackRock Event Driven Equity Fund | 175,388 | 1.03% | $2.28M | 0.05% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 154,179 | 0.90% | $1.75M | 0.01% | Jul 31, 2026 |
| Nexpoint Merger Arbitrage Fund | 135,138 | 0.79% | $1.82M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 88,107 | 0.52% | $1.19M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 73,533 | 0.43% | $955.93K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 67,639 | 0.40% | $879.31K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 62,889 | 0.37% | $817.56K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 48,184 | 0.28% | $648.07K | 0.04% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Portfolio | 41,700 | 0.24% | $560.87K | 0.07% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 41,090 | 0.24% | $552.66K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kathleen P. Gallagher | See Remarks, Director | 119,729 | 0.70% | Sep 22, 2026 |
| Husam Younis | Chief Scientific Officer | 41,441 | 0.24% | Sep 22, 2026 |
| Steven George Hughes | Chief Medical Officer | 51,638 | 0.30% | Sep 22, 2026 |
| Brendan R. Winslow | Chief Financial Officer | 36,859 | 0.22% | Sep 22, 2026 |
| Stephanie Kenney | See Remarks | 33,085 | 0.19% | Sep 22, 2026 |
| Rocio Martin Hoyos | Chief Strategy Officer | 38,340 | 0.22% | Sep 22, 2026 |
| W. Michael Flanagan | Director | 31,974 | 0.19% | Sep 22, 2026 |
| Sarah Boyce | Director | 138,668 | 0.81% | Sep 22, 2026 |
| Carsten Boess | Director | 11,005 | 0.06% | Mar 2, 2026 |
| Simona Skerjanec | Director | 5,902 | 0.03% | Mar 2, 2026 |
| Troy Edward Wilson | Director | 11,731 | 0.07% | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven George Hughes Chief Medical Officer | Sep 18, 2026 | Tax withholding | −21,459 | $8.95 | $192.06K | 51,638 |
| Stephanie Kenney See Remarks | Sep 18, 2026 | Tax withholding | −2,375 | $8.95 | $21.26K | 33,085 |
| Brendan R. Winslow Chief Financial Officer | Sep 18, 2026 | Tax withholding | −6,742 | $8.95 | $60.34K | 36,859 |
| Rocio Martin Hoyos Chief Strategy Officer | Sep 18, 2026 | Tax withholding | −8,320 | $8.95 | $74.46K | 38,340 |
| Sarah Boyce Director | Sep 18, 2026 | Tax withholding | −126,418 | $8.95 | $1.13M | 138,668 |
| Kathleen P. Gallagher See Remarks, Director | Sep 18, 2026 | Tax withholding | −11,632 | $8.95 | $104.11K | 119,729 |
| Husam Younis Chief Scientific Officer | Sep 18, 2026 | Tax withholding | −11,216 | $8.95 | $100.38K | 41,441 |
| W. Michael Flanagan Director | Sep 18, 2026 | Tax withholding | −22,812 | $8.95 | $204.17K | 31,974 |
| Husam Younis Chief Scientific Officer | Apr 20, 2026 | Award | +30,000 | – | – | 52,657 |
| Steven George Hughes Chief Medical Officer | Apr 20, 2026 | Award | +30,000 | – | – | 73,097 |
| Rocio Martin Hoyos Chief Strategy Officer | Apr 20, 2026 | Award | +30,000 | – | – | 46,660 |
| Kathleen P. Gallagher See Remarks, Director | Apr 20, 2026 | Award | +102,500 | – | – | 131,361 |
| Brendan R. Winslow Chief Financial Officer | Apr 20, 2026 | Award | +30,000 | – | – | 43,601 |
| Stephanie Kenney See Remarks | Apr 20, 2026 | Award | +30,000 | – | – | 35,460 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Atrium Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,946 shares on Aug 21, 2026 over the last 90 days.
See a number that looks wrong?